Aviptadil
VIP / Vasoactive intestinal peptide / RLF-100
- Peptide length
- 28 amino acids
Synthetic VIP peptide
Open the sources to check how the studies were done and what they can support.
A synthetic form of vasoactive intestinal peptide studied in respiratory and other clinical settings.
- Family
- Vasoactive intestinal peptide
- Research target
- VIP receptors
- Molecular form
- Synthetic VIP peptide
What to know about the research
The randomized TESICO COVID-19 trial did not show a significant improvement in clinical outcomes with aviptadil. Earlier signals must be read alongside that result.
Check the exact compound
Keep standalone aviptadil, combination products and route-specific formulations separate.
What supports this entry?
The reference list is available. A statement-by-statement source check has not been completed for this entry.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
How we prepare and correct these entries